Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FARSTEP-R: Real-World Faricimab Treat-and-Extend in Macular Edema After Retinal Vein Occlusion
ChiCTR2600128301Phase 4Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in branch retinal vein occlusion (BRVO), central retinal vein occlusion with macular edema and macular edema, sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Change in visual acuity from baseline to week 48. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
branch retinal vein occlusion (BRVO)central retinal vein occlusion with macular edemamacular edema
Beyond the preview
Go deeper on ChiCTR2600128301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128301.